3-Methyl-4-(1-methylethyl)benzenemethanol | 1012068-54-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 3-Methyl-4-(1-methylethyl)benzenemethanol
• 英文别名: (3-methyl-4-propan-2-ylphenyl)methanol
• CAS: 1012068-54-0
• 化学式: C₁₁H₁₆O
• 分子量: 164.24
• InChiKey: RRMPOXUCVQUKAE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
  申请人：Rodgers D. James

  公开号：US20070135461A1

  公开（公告）日：2007-06-14

  The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

  本发明提供了杂环取代的吡咯并[2,3-b]吡啶和杂环取代的吡咯并[2,3-b]嘧啶，可以调节雅努斯激酶的活性，并且在治疗与雅努斯激酶活性相关的疾病中具有用处，例如免疫相关疾病、皮肤疾病、髓增生性疾病、癌症和其他疾病。
• HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS
  申请人：Rodgers James D.

  公开号：US20090181959A1

  公开（公告）日：2009-07-16

  The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

  本发明提供了杂环取代的吡咯并[2,3-b]吡啶和杂环取代的吡咯并[2,3-b]嘧啶，可调节Janus激酶的活性，并可用于治疗与Janus激酶活性相关的疾病，包括免疫相关疾病、皮肤疾病、髓系增生性疾病、癌症和其他疾病。
• 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
  申请人：Doherty A. George

  公开号：US20070043014A1

  公开（公告）日：2007-02-22

  The present invention encompasses compounds of Formula I: (I) as well as the pharmaceutically acceptable salts thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.

  本发明涵盖化合物I式：(I)，以及其药学上可接受的盐。该化合物对于治疗免疫介导的疾病和病况，如骨髓、器官和组织移植排斥等非常有用。药物组合物和使用方法也包括在内。
• Kinase Inhibitors
  申请人：Spada Lon T.

  公开号：US20110263611A1

  公开（公告）日：2011-10-27

  The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.

  本发明涉及药物输送系统，包括眼部植入物，其中包括有机分子，能够调节酪氨酸激酶信号传导，以调节、调节和/或抑制异常细胞增殖，与聚合物结合使用，该聚合物可用于控制、修改、调节和/或减缓治疗成分释放到放置该复合材料的眼部环境中。
• Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
  申请人：Rodgers James D.

  公开号：US20140018374A1

  公开（公告）日：2014-01-16

  The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

  本发明提供了杂环取代的吡咯[2,3-b]吡啶和杂环取代的吡咯[2,3-b]嘧啶，其调节Janus激酶的活性，并且在治疗与Janus激酶活性相关的疾病中具有用处，包括但不限于免疫相关性疾病、皮肤疾病、髓样增生性疾病、癌症和其他疾病。